Pioneering longevity therapies.
We develop longevity therapies in overlooked areas of healthcare.
Epigenetic reprogramming
Goldstar Biotech is pioneering innovative therapies aimed at rejuvenating aged cells through epigenetic reprogramming. Leveraging cutting-edge technologies such as epigenetic reprogramming and AI, we uncover the epigenetic features of ageing and develop interventions to restore rejuvenated function.
According
to
the
World
Health
Organization,
thenumber
of
people
aged
60
and
above
is
expectedto
reach
2.1
billion
by
2050,
up
from
900
million
in2015.
This
demographic
shift
is
driving
a
significanteconomic
incentive
for
companies
to
develop
thesetechnologies
as
they
can
reduce
healthcare
costsand
enable
older
adults
to
remain
active
in
theworkforce.
900 million
2.1 billion
2015
2050
A slowdown in ageing that increases life expectancy by 1 year is worth $38 trillion, and by 10 years, $367 trillion*
Therapeutic targets
Liver-specific conditions
Cardiovascular diseases
Neurodegeneration diseases
THE PROCESS
The Discovery Engine developed by Goldstar Biotech employs functional genomics alongside machine learning techniques toassess numerous reprogramming interventions in eachexperiment.
During each experimental iteration, we administer thousandsof distinct combinations of reprogramming factors to cells,analyze cell profiles using single-cell multi-omics methods, andemploy machine learning algorithms to deduce the effects of reprogramming on cellular function. Subsequently, we verify the most promising interventions through a series of functional assays.
Learn about the science behind.